| AstraZeneca40 programs in shared conditions | 10 · 6 with both in phase 3Carcinoma, Non-Small-Cell Lung, Leukemia, Lymphocytic, Chronic, B-Cell, Lupus Erythematosus, Systemic +7 | benralizumab, tezepelumab, BFF MDI +8 | - AstraZeneca’s acalabrutinib vs ibrutinib (EU rights: Johnson & Johnson) (Leukemia, Lymphocytic, Chronic, B-Cell, NCT02477696)
- AstraZeneca’s Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F vs daratumumab (most trials: Johnson & Johnson) (Multiple Myeloma, NCT07391657)
- AstraZeneca’s Actinium-225 vs apalutamide (US & EU rights: Johnson & Johnson) (Prostatic Neoplasms, NCT07611110)
- and 6 more
|
| Qilu Pharmaceutical Co., Ltd.24 programs in shared conditions | 10 · 5 with both in phase 3Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Multiple Myeloma +7 | tezepelumab, QL2107, QL1203 +9 | - Qilu Pharmaceutical Co., Ltd.’s QLS4131 in a combination vs daratumumab (most trials: Johnson & Johnson) (Multiple Myeloma, NCT07933432)
- Qilu Pharmaceutical Co., Ltd.’s QL2109 in a combination vs daratumumab (most trials: Johnson & Johnson) (Multiple Myeloma, NCT07400744)
- Qilu Pharmaceutical Co., Ltd.’s QL2109 in a combination vs Daratumumab and Hyaluronidase-fihj (most trials: Johnson & Johnson) (Multiple Myeloma, NCT06742138)
- and 1 more
|
| GlaxoSmithKline17 programs in shared conditions | 6 · 2 with both in phase 3Multiple Myeloma, Prostatic Neoplasms, Asthma +3 | felcorekibart, HFA-152a, norflurane +3 | - GlaxoSmithKline’s belantamab mafodotin in a combination vs daratumumab (most trials: Johnson & Johnson) (Multiple Myeloma, NCT04246047)
- GlaxoSmithKline’s belantamab mafodotin in a combination vs daratumumab (most trials: Johnson & Johnson) (Multiple Myeloma, NCT06868654)
- GlaxoSmithKline’s belantamab mafodotin in a combination vs daratumumab (most trials: Johnson & Johnson) (Multiple Myeloma, NCT06868667)
- and 1 more
|
| Regeneron Pharmaceuticals8 programs in shared conditions | 5 · 1 with both in phase 3Multiple Myeloma, Carcinoma, Non-Small-Cell Lung, Dermatitis, Atopic +2 | linvoseltamab | - Regeneron Pharmaceuticals’ linvoseltamab vs daratumumab (most trials: Johnson & Johnson) (Multiple Myeloma, NCT07393282)
- Johnson & Johnson’s JNJ-95475939 in a combination vs dupilumab (US rights: Regeneron Pharmaceuticals) (Dermatitis, Atopic, NCT06881251)
- Regeneron Pharmaceuticals’ linvoseltamab in a combination vs daratumumab (most trials: Johnson & Johnson) (Multiple Myeloma, NCT07222761)
- and 1 more
|
| AbbVie24 programs in shared conditions | 15 · 5 with both in phase 3Carcinoma, Non-Small-Cell Lung, Colitis, Ulcerative, Colorectal Neoplasms +12 | telisotuzumab adizutecan, ABBV-1480, vedolizumab +5 | - Johnson & Johnson’s bleximenib added to venetoclax (US & EU rights: AbbVie) (Leukemia, Myeloid, Acute, NCT06852222)
- AbbVie’s etentamig in a combination vs daratumumab (most trials: Johnson & Johnson) (Multiple Myeloma, NCT07728188)
- AbbVie’s Anti-BCMA/CD38/CD3 Trispecific Antibody ABBV-2001 in a combination vs daratumumab (most trials: Johnson & Johnson) (Multiple Myeloma, NCT06892522)
- and 3 more
|